Navigation Links
Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting
Date:6/1/2009

so presented(3) . Fifty-six patients were enrolled with daily oral doses of AT-101 given for 21 of 28 days in repeated cycles. The treatment was well tolerated, with a low incidence of serious adverse events and no unique central nervous system toxicities. Responses were evaluated in 43 patients and included one confirmed partial response and 8 patients with stable disease, representing half of the patients still alive at the time of analysis. Progression-free survival (PFS) in these patients ranged from 8 to 13 months. Determination of the impact of AT-101 on overall survival (OS), the primary endpoint, is ongoing.

AT-101 in Lung Cancer

Reports from two studies in lung cancer also showed promising signals of antitumor effect. The first presentation described results from a randomized, double-blind, placebo-controlled Phase II trial in 105 patients who had received one prior chemotherapy regimen for non-small cell lung cancer (NSCLC)(4). While the primary endpoint, a statistically significant improvement in PFS, was not met, the docetaxel plus AT-101 arm demonstrated a positive trend in OS, as reflected in the Kaplan-Meier curves (hazard ratio 0.82). This group also demonstrated a 33 percent increase in median survival and a 34 percent increase in 6-month survival compared to the docetaxel plus placebo arm. Common adverse events included fatigue (18 percent), anemia (18 percent) and dyspnea (18 percent). Using NSCLC cell lines, a genomic profile predicting response to AT-101 was developed in collaboration with Duke University. Opportunities to validate this biomarker will be pursued in future trials.

The second presentation reported on an open-label, Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer (SCLC) who had received prior platinum-based first line chemotherapy(5). The Phase II portion of the trial included 25 patients div
'/>"/>

SOURCE Ascenta Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... Corporation (NASDAQ: UTHR ) announced today that Roger ... Therapeutics, will provide an overview and update on the company,s ... New York City . The presentation ... Thursday, June 4, 2015, at 11:00 AM Eastern Time, and ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of Jain PharmaBiotech,s ... Technologies, Markets, and Companies" to their ... This report deals with therapeutic ... at improving patient care by monitoring drug ...
(Date:5/28/2015)... , May 27, 2015 Research ... of Jain PharmaBiotech,s new report "Cell Therapy ... offering. This report describes and evaluates ... started to play an important role in the ... replacing the old fashioned bone marrow transplants. Role ...
(Date:5/28/2015)... May 28, 2015 DryLet, LLC ... in applications such as animal waste reduction, bioremediation, ... reduction in wastewater treatment plants and restaurant kitchen ... World Pork Expo, June 3-5 in Des Moines, ... in a Wall Street Journal article because of ...
Breaking Biology Technology:Global Therapeutic Drug Monitoring Market 2015-2024 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2
... the enzyme market is significant and estimated at €3.4 billion ... sold in many different industry segments. These segments are Detergents, Food, ... ... (PRWEB) July 8, 2008 -- According to CBDM.T®, The market and ...
... PRINCETON, N.J., July 7 Medarex, Inc.,(Nasdaq: MEDX ... to,listen to a live webcast of its 2008 R&D ... 2008 at 8:00 a.m. Eastern Time and is expected ... will,provide an overview of the company,s strategy, progress and ...
... DIEGO, July 7 AMN Healthcare Services,Inc. (NYSE: ... United,States, will host its quarterly conference call to discuss ... p.m. Eastern Time. The,company expects to issue an earnings ... 4:00 p.m. Eastern Time., A live webcast of ...
Cached Biology Technology:CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 2CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 3Medarex Announces July 10 Live Webcast of R&D Day Event 2AMN Healthcare Services to Host 2008 Second Quarter Earnings Conference Call on Wednesday, August 6, 2008 2
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... at UT Southwestern Medical Center say there are at ... colon cancer, far more than scientists previously thought. ... 2011 Cancer Research (Priority Reports), researchers are suggesting a ... and pathways simultaneously. Current cancer treatments target just one ...
... Boston, MA Using nanotechnology to engineer sensors ... Women,s Hospital (BWH) have developed a platform technology for ... in both science and medicine by providing the ability ... and develop effective therapeutics. These findings are published in ...
... amount of pollution that is showing up in data from ... red butterfly in the skies over southern part of the ... image of the pollution from agricultural fires in central Africa ... the period from July 7 to 12, 2011. It was ...
Cached Biology News:Researchers provide means of monitoring cellular interactions 2NASA's Aura satellite measures pollution 'butterfly' from fires in central Africa 2
Determin interaction of your protein with Echelons lipids...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... tubes are used to store 2.0 ml ... uniform walls for uniform heat transfer and ... caps. The O-rings are made of polyethylene ... from -55 to 150 degrees C. Supplied ...
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
Biology Products: